The CXC chemokine receptor 3 (CXCR3) has been linked to autoimmune and inflammatory disease, allograft rejection, and ischemic nephropathy. CXCR3 is expressed on endothelial and smooth muscle cells. Although a recent study posited that antagonizing of CXCR3 function may reduce atherosclerosis, the role of CXCR3 in controlling physiological vascular functions remains unclear. This study demonstrates that disruption of CXCR3 leads to elevated mean arterial pressures in anesthetized and conscious mice, respectively. Stimulation of isolated resistance vessels with various vasoconstrictors showed increased contractibility in CXCR3Ϫ/Ϫ mice in response to angiotensin II (ANG II) and a decreased vasodilatation in response to acetylcholine (ACh). The increased contractibility was related to higher ANG II type 1 receptor (AT1R) expression, whereas the decreased vasodilatation was related to lower M3-ACh receptor expression in the mesenteric arteries of CXCR3Ϫ/Ϫ mice compared with wild-type mice. The vasodilatatory response to ACh could be antagonized by the nonselective ACh receptor antagonist atropine and the selective M3 receptor antagonist 4-DAMP, but not by M1, M2, and M4 receptor antagonists. Additionally, EMSA studies revealed that transcription factors SP-1 and EGR-1 interact as a complex with the murine AT1R promoter region. Furthermore, we could show increased expression of SP-1 in CXCR3Ϫ/Ϫ mice indicating an imbalanced SP-1 and EGR-1 complex formation which causes increased AT1R expression and hypertension. The data indicate that CXCR3 receptor is important in vascular contractility and hypertension, possibly through upregulated AT1R expression.
angiotensin II type 1 receptor; acetylcholine receptor; CXCR3 knockout mice; EMSA; transcription factors; vascular contractility CXC CHEMOKINE RECEPTOR 3 (CXCR3), the receptor for chemokines such as CXCL9/MIG, CXCL10/IP-10, and CXCL11/I-TAC, is not only important in lymphocyte recruitment to inflammatory sites but is also involved in T cell activation (46) . Additionally, IP-10 has been demonstrated to inhibit proliferation of human endothelial cells (28) and bone marrow-derived hematopoietic progenitors (40) . CXCR3-deficient mice displayed resistance to the development of acute allograft rejection following cardiac transplantation, probably due to reduced intragraft accumulation of activated T cells (13) , and CXCR3 has been suggested to support renal microvascular damage (35) . Moreover, CXCR3 has been linked to the pathogenesis of atherosclerosis (14) , and recent studies demonstrated that an antagonist of CXCR3 can attenuate atherosclerotic lesion formation by blocking direct migration of CXCR3 ϩ effector cells from the circulation into the atherosclerotic plaques (51) . However, serious adverse effects of CXCR3 deletion have been also identified in models of fibrotic diseases: CXCR3Ϫ/Ϫ mice exhibited increased mortality with progressive interstitial pulmonary fibrosis, which occurred without increased inflammatory cell recruitment (19) , and CXCR3 deletion has been shown to promote progressive renal fibrosis, suggesting that activation of CXCR3 may be useful in antifibrotic therapeutic strategies (32) . Furthermore, diverse phenotypes have been observed in CXCR3Ϫ/Ϫ mice following several inflammatory and autoimmune challenges, and previous studies proposed that the relationship between CXCR3 expression and recruitment of activated T cells is not a universal feature of the phenotype of CXCR3-null mice (27) .
Essential hypertension is a major risk factor for developing cardiovascular disease (36) . The pathogenesis of hypertension is multifactorial and influenced by both genetic and environmental factors (26) . Numerous genes are involved in blood pressure (BP) regulation in mammalians and these genes affect renal hemodynamics, ion and water transport, and regulation of hormones and humeral agents, such as aldosterone, catecholamines, endothelin, prolactin, proopiomelanocortin, renin, and vasopressin (2, 24) . Within the vessel, CXCR3 receptors are expressed in endothelial cells (10) as well as in vascular smooth muscle cells (14) , which are important in the dynamic regulation of the circulation and have a crucial role in the pathogenesis of hypertension (43) . Little is known regarding the basic in vivo functions of the CXCR3 receptor in cardiovascular physiology and its role in regulating BP. This study investigated whether the CXCR3 receptor is involved in BP regulation and vascular reactivity.
This report describes that the loss of CXCR3 promotes hypertension, with a concomitant increased expression of angiotensin II type 1 receptor (AT1R) and decreased expression of M3 acetylcholine (ACh) receptor, suggesting that both increased vasoconstriction and decreased vasodilatation contribute to hypertension in CXCR3Ϫ/Ϫ mice. Additionally, the transcription factor SP-1, which expression is upregulated in CXCR3Ϫ/Ϫ mice, bound to the murine AT1R promoter re-gion. We suggest that an imbalance of SP-1/EGR-1 complex formation is involved in the increased AT1R expression and hypertension in CXCR3Ϫ/Ϫ mice.
METHODS

Generation and Genotyping of CXCR3 Chemokine Receptor Mutant Mice
Generation of CXCR3 receptor knockout mice was performed as described recently (12) . The original hybrid strain (C57BL/6) carrying a mutation of the CXCR3 receptor was first generated and backcrossed to BALB/c mice. Heterozygous (CXCR3ϩ/Ϫ) mice were mated to yield CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ littermates. CXCR3Ϫ/Ϫ mice were then backcrossed with BALB/c mice to obtain Ͼ14th generation transgenic mice. The experiments exclusively used Ͼ14th generation transgenic mice. All animal experiments were performed according to the guidelines of the National Institutes of Health as well as the German law for the welfare of animals and were approved by local authorities. Genotyping was performed using primers recognizing genomic DNA sequences upstream, inside, and downstream of the inserted PGK neomycin cassette. The following primers were used: CXCR3 forward: 5Ј-GTGCTAGATGCCTCGGACTTTG-3Ј; CXCR3 reverse: 5Ј-CTCCCACAAAGGCATAGAGC-3Ј; CXCR3 neomycin forward: 5Ј-CAAGATGGATTGCACGCAGG-3Ј.
BP Measurement
Mice were anesthetized with intraperitoneal ketamine and tracheotomized as described previously (15, 25) . Catheters were inserted into the internal jugular vein and the carotid artery for fluid administration and BP monitoring (World Precision Instruments). BP was recorded following 1 h of equilibration (0.9% NaCl, 1% of body wt) as described recently (4). Conscious BP was measured using TA11PA-C10 transmitters (Data Sciences International) implanted into the carotid artery. Finally, BP was measured via telemetry 7 days after catheter placement in freely moving unanesthetized mice.
Saline Loading Study
Acute sodium load. After a 60-min stabilization period after the catheter insertion and a baseline 60-min period for BP measurement, a normal saline load equivalent to 5% body wt was infused intravenously for 30 min. Urine was collected during saline loading via suprapubic cystostomy; three more urine collection periods of 60 min each were obtained after loading. Blood (50 l) was obtained from the femoral artery before the load and at the end of the last urine collection. For chronic studies, CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice were maintained on a baseline regular pelleted diet (0.4% NaCl) 1 wk before and after implantation of the BP radio transmitter device, and provided free access to water and food. Following a 24-h measurement period, the mice were switched to a high-sodium regular pelleted diet (0.8% NaCl) for a further week with an additional measurement period of 24 h at the end of the second week. All animals received the same weight of food and were given free access to water. The weights of the mice remained constant during the experimental period. At the end of the second experimental period, mice were killed.
Vascular Tension Measurements
Mesentery arteries of CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ were prepared under a dissecting microscope and placed in oxygenized cold Krebs Ringer bicarbonate solution (KRB) containing (in mmol/l) 119.1 NaCl, 4.7 KCl, 1.2 MgSO 4, 1.2 KH2PO4, 25.0 NaHCO3, 2.5 CaCl2, and 5.5 glucose. In high-K ϩ solution (125 mmol/l K ϩ ), NaCl was replaced by an equimolar concentration of KCl. All buffer ingredients, as well as the test agents, were obtained from Sigma. Furthermore, vascular preparations were mounted on two stainless steel wires in an isometric myograph (Myograph model 410A, J.P. Trading); one wire connected to a force transducer (Kistler Morse DSC6) was used to record isometric force development, and with the other wire being connected to a displacement device, as described previously (45) . Arteries were stretched to their optimal luminal diameter using an active length tension protocol with 125 mmol/l K ϩ as activating stimulus (6) . The optimal luminal diameter was established as the maximal force created by depolarization of the vascular smooth muscle cells in response to 125 mmol/l K ϩ . After establishing the optimal lumen diameter (as a standardization procedure of the individual vascular preparations), the vascular preparations were permitted to equilibrate in fresh 37°C oxygenized KRB solution for 15 min and stimulated using the following substances: phenylephrine, vasopressin, endothelin I, ANG II, ACh, atropine, himbacine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), pirenzepine, and p-fluoro-hexahydro-sila-difenidol. Experimental concentrations were set to maintain selectivity of the antagonists according to published concentrations (16) .
Two-Dimensional and Conventional Western Blot Experiments
Mouse mesentery artery and kidney samples (pooled from 6 mice for each experiment) were homogenized in 175 l of lysis buffer (7 mol/l urea, 2 mol/l thiourea, 4% CHAPS, and 30 mmol/l Tris) with a microtissue grinder, followed by three rounds of sonication in an ice bath sonicator. Lysates were kept on ice for 30 min and centrifuged for 1 h at 16,000 g. Protein concentrations of supernatants were determined using Advanced Protein Assay agents (Cytoskeleton) in triplicate and the results were averaged. Equal amounts of protein (350 -400 g) were loaded to sample cups in the focusing tray. Two-dimensional (2D) electrophoresis of proteins was performed as described in the ReadyStrip IPG Strip Instruction Manual (Bio-Rad). IPG strips (pH 3-10 nonlinear) were rehydrated by adding 215 l of buffer containing 7 mol/l urea, 2 mol/l thiourea, 4% CHAPS, 100 mmol/l DTT (dithiothreitol), and 8% IPG buffer (Bio-Lyte 3-10, Bio-Rad) to each channel in the rehydration tray overnight. First, dimension separations were performed by the PROTEAN IEF cell (Bio-Rad) using the cup loading method under the following focusing conditions: 1,000 V for 90 min (slow ramp), 3,500 V for 90 min (slow ramp), and 7,000 V for 120 min (rapid ramp). For the second-dimension electrophoresis, the focused IPG strips were equilibrated in a reduction buffer (37.5 mmol/l Tris ⅐ HCl, pH 8.8, 6 mol/l urea, 20% glycerol, 2% SDS, and 1% DTT) at 25°C for 15 min. The strip was then equilibrated in an alkylation buffer (37.5 mmol/l Tris ⅐ HCl, pH 8.8, 6 mol/l urea, 20% glycerol, 2% SDS, 0.002% bromophenol blue, and 2.5% iodoacetamide) at 25°C for 15 min. Proteins were separated by 12% SDS-PAGE, transblotted onto a nitrocellulose membrane, and probed with primary antibodies (anti-AT1R antibody, sc-1173, Santa Cruz Biotechnology, 1:1,000) followed by secondary antibodies. The specificity of the AT1R antibody was confirmed by lysates from a murine podocyte cell line stably transfected with Flag-tagged human AT1R using 2D immunoblotting and immunoprecipitation methods (15a). For M3 ACh receptor detection, protein lysates were separated via conventional 10% SDS-PAGE, transblotted onto a nitrocellulose membrane, and probed with primary antibodies (anti-M3 ACh receptor antibody, sc-7474, Santa Cruz Biotechnology, 1:500). Blocking peptide (sc-7474p) was employed to confirm the specificity of the antibody. Chemiluminescent signals of AT1R, M3 ACh receptor, and ␤-actin (sc-1615, Santa Cruz Biotechnology) were detected with a LumiImager (Roche) and X-ray film developer and quantified using the LumiAnalyst program (Roche). In conventional Western blot experiments, antibodies for detection of EGR-1 protein (Santa Cruz Biotechnology, sc-110) and SP-1 protein (Millipore) in whole kidney lysate were used according to the manufacturer's instructions.
EMSA Experiments
Generation of recombinant plasmids. DNA fragments encoding both full-length and truncated versions of murine EGR-1 and SP-1 protein were amplified from a cDNA bank obtained from an immorto mouse proximal tubule (M-PT) cell line generated from an "immortomouse" (H-2K b -tsA58 transgenic mouse) (18) . Murine EGR-1 fulllength protein (NM_007913; aa: 1-533), a truncated version of EGR-1 protein containing the zinc-finger-DNS-binding domains (DBD; EGR-1-DBD; aa: 327-418), SP-1 full-length protein (AF062566; aa: 1-781), and a SP-1 protein mutant comprising the DBD (SP-1-DBD; aa: 618-711) were amplified by PCR. Resulting PCR fragments were cloned blunt end into pCR4blunt-TOPO using the TOPO-cloning system (Invitrogen), sequenced, and subcloned into EcoRI/NotI sites of the pGEX-4T-1 expression vector (Amersham Bioscience/GE Healthcare).
Expression and Purification of Recombinant Proteins
To produce murine GST-EGR-1 or GST-SP-1 fusion proteins, Escherichia coli BL21 cells were transformed using the different pGEX constructs. Briefly, an overnight culture of E. coli transformed with the expression vectors was diluted 1:20 with LB medium containing 1% glucose, incubated at 37°C, and agitated at 220 rpm until an OD 600 of 0.8 was reached. Expression was induced by adding 1 mmol/l isopropyl-1-thio-␤-D-galactopyranoside (IPTG), and suspension was incubated at 25°C for a further 2.5 h. Subsequently, cells were harvested, resuspended in phosphate-buffered saline containing protease inhibitor mix (Complete, Roche Molecular Biochemicals), and sonicated on ice. Triton X-100 (1%) and 1 mg/ml lysozyme were added, the suspension was mixed and incubated on ice for another 30 min, and cellular debris was pelleted by centrifugation (16,000 g, 20 min, 4°C). Recombinant proteins were isolated from bacterial lysates using glutathione-sepharose beads (Amersham Bioscience/GE Healthcare) according to the manufacturer's instructions. Proteins were eluted (50 mmol/l Tris⅐HCl, pH 8.0, containing 10 mmol/l glutathione), dialyzed against PBS, and stored in aliquots at Ϫ80°C until further use. Recombinant human SP-1 protein (ALX-201-106-R050) and EGR-1 protein (ALX-201-074) were obtained from Biochemicals.
EMSA
The double-strand mouse AT1R oligonucleotide corresponding to the nucleotide sequence Ϫ230/Ϫ51 in the murine AT1R promoter (NM_177322.2), which contains a putative SP-1/EGR-1 overlapping binding sites, was identified using the Alibaba 2.1 net-based search tool (www.gene-regulation.com). The oligonucleotide was amplified by PCR using Go-Taq DNA-polymerase (Promega) from genomic mouse DNA using the following oligonucleotide primers: forward: 5Ј-CAGGACCAGCTGAGCTTGGATC-3Ј; reverse: 5Ј-GGGGGAC-GTTGCTACTCCGCAGGTTCC-3Ј. AT1R sequence was confirmed by DNA sequencing using internal primers (forward: 5Ј-CACATCG-GTGACTGGCAGCAGGG-3Ј; reverse: 5Ј-CCTAAGGCTTTGCAC-TCCTCCCTCG-3Ј). The resulting 150-bp PCR fragment was purified using the High Pure PCR Product Purification Kit (Roche Molecular Biochemical) as directed by the manufacturer. AT1R (5 pmol) oligonucleotide was 3Ј-biotinylated using the 3Ј-end DNA labeling kit (Perbio) as described by the manufacturer. The labeling process was stopped by adding 2.5 l 0.2 mol/l EDTA (pH 8.0) to a 50-l reaction volume, and the labeled probe was isolated via phase-separation after adding 50 l of chloroform:isoamyl alcohol (24:1), and subsequently purified using a High Pure PCR Product Purification Kit (Roche Molecular Biochemical). For competition experiments, the unlabeled AT1R promoter fragment was used as a specific unlabeled competitor. Additionally, SP-1 and EGR-1 consensus oligonucleotides were employed as biotin-labeled positive controls, and specific unlabeled competitors were obtained from Panomics (SP-1, AY1043P; EGR-1 AY1303P) as described recently (22, 23) . DNA/protein complex formation was performed in a total reaction volume of 20-to 28-l interaction buffer (40 mmol/l HEPES/KOH, pH 7.9), 240 mmol/l KCl, 20 mmol/l MgCl 2, 2 mmol/l Spermidin, 6% Ficoll using 25 ng preshared poly dI-dC (Amersham Bioscience) as a nonspecific competitor, and 20 mmol/l Betain (Sigma). In some samples, a 100-to 200-fold molar excess of unlabeled oligonucleotides was added as specific competitors before the incubation with the labeled AT1R promoter region and incubated 15 min on ice. Following the addition of biotin-labeled oligonucleotide, samples were incubated for a further 30 min at room temperature. DNA/protein complexes were separated on nondenaturating 6% polyacrylamide gels in 0.5ϫ TBE (45 mmol/l Tris, 32.3 mmol/l boric acid, 1.25 mmol/l EDTA, pH 8.3) at 100 V for Fig. 1 . Disruption of CXC chemokine receptor 3 (CXCR3) increases blood pressure. A: mean arterial pressure (MAP) in anesthetized, catheterized CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. Blood pressures were significantly higher in CXCR3Ϫ/Ϫ mice before and after acute sodium load. B: MAP in conscious freely moving mice on a low-or a high-sodium diet. Blood pressures in CXCR3Ϫ/Ϫ mice were considerably higher on a low-sodium diet, and further increased in response to a high-sodium diet, a phenomenon observed in CXCR3ϩ/ϩ mice (*P Ͻ 0.05, CXCR3Ϫ/Ϫ vs. CXCR3ϩ/ϩ mice, t-test; **P Ͻ 0.01;°P Ͻ 0.05, CXCR3Ϫ/Ϫ mice, high-sodium diet vs. CXCR3Ϫ/Ϫ mice, low-sodium diet, t-test).
1.5 h at room temperature. Following electrophoresis, gels were electrotransferred onto PVDF membranes (0.5% TBE, 100 V, 60 min). After the blotting procedure, membranes and DNA/protein complexes were cross-linked using 10-min UV light incubation and incubated for 15 min at room temperature in prewarmed (50°C) blocking solution (0.5% blocking reagent, Roche Molecular Biochemical), 5 mmol/l maleic acid, 7.5 mmol/l NaCl, pH 7.5. Subsequently, bands were visualized by streptavidin-horseradish peroxidase reaction using the Chemiluminescent Nucleic Acid Detection Module Kit (Perbio).
Statistical Analysis
Data are expressed as means Ϯ SE and were analyzed by ANOVA for repeated measures when comparing within groups and one-way ANOVA when comparing among groups. Student's t-test was used for a two-group comparison and Scheffé's test for multiple comparisons. P Ͻ 0.05 was considered statistically significant.
RESULTS
BP Measurements in CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ Mice
To test the hypothesis that CXCR3 knockout mice are prone to arterial hypertension, baseline BPs were first measured in anesthetized, catheterized CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. Mean arterial pressure (MAP) in CXCR3Ϫ/Ϫ mice (76 Ϯ 3 mmHg, n ϭ 8) was considerably raised compared with CXCR3ϩ/ϩ mice (70 Ϯ 2 mmHg, n ϭ 15). An acute sodium load (5% of body wt) increased BPs in CXCR3Ϫ/Ϫ mice (89 Ϯ 3 mmHg, n ϭ 8) compared with CXCR3ϩ/ϩ mice (70 Ϯ 3 mmHg; Fig. 1A ). To confirm these data, BPs were measured in conscious CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice on either a low (0.4% NaCl)-or high (0.8% NaCl)-sodium diet. MAP was significantly raised in CXCR3Ϫ/Ϫ, including those on a low-sodium (126 Ϯ 2 mmHg, n ϭ 3) and a high-sodium diet (134 Ϯ 3 mmHg, n ϭ 3), compared with CXCR3ϩ/ϩ mice on a low-sodium (107 Ϯ 3 mmHg, n ϭ 3) and a high-sodium (109 Ϯ 3 mmHg, n ϭ 3) diet. The high-sodium diet markedly increased MAP in CXCR3Ϫ/Ϫ mice by ϳ8 mmHg, compared with CXCR3Ϫ/Ϫ mice on a low-sodium diet, but did not change MAP in CXCR3ϩ/ϩ mice (Fig. 1B) .
Vascular Response to Vasoconstrictors in CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ Mice
To further characterize arterial hypertension in CXCR3Ϫ/Ϫ mice, isolated resistance vessels (mesenteric arteries) were stimulated using the AT1R agonist ANG II (10 Ϫ12 -10 Ϫ6 mol/l; Fig. 2A) , the nonselective ␣-adrenergic receptor agonist phenylephrine (10 Ϫ6 mol/l ( Fig. 2A) . Responses of all other vasoconstrictors were not significantly changed between CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice.
Vascular Response to Vasodilatators in CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ Mice
To test the hypothesis that CXCR3 receptors influence the vasodilatatory capabilities of resistance vessels, vasodilata- tion in response to ACh (10 Ϫ11 Ϫ 5 ϫ 10 Ϫ4 mol/l; Fig. 3A ) was tested. Preconstriction of mesenteric arteries was induced by stimulation with 10 Ϫ6 mol/l phenylephrine (EC50 value in vasoconstriction experiments), because vasoconstructive response to phenylephrine did not differ between CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. Phenylephrine has been described in the previous literature on this kind of experiments (45) . Subsequent increases in ACh concentrations were added to the perfusion chamber. Vasodilatation in response to ACh was significantly reduced in CXCR3Ϫ/Ϫ mice and reached statistical significance at concentrations of 10 Ϫ7 Ϫ 5 ϫ 10 Ϫ4 mol/l (Fig. 3A) . To better understand the type of muscarinic ACh receptor involved in the vasodilatatory response, different muscarinic receptor antagonists were used to antagonize the effect of ACh (Fig. 3, B and C) . Vasodilatation in mesenteric arteries in response to ACh (10 Ϫ5 mol/l) could be antagonized by the nonselective ACh receptor antagonist atropine (10 Ϫ6 mol/l) and the relatively selective M3 receptor antagonist 4-DAMP (10 Ϫ6 mol/l) but not by the relatively selective antagonists for the M1 (10 Ϫ5 mol/l pirenzepine), M2/M4 (10 Ϫ6 mol/l himbacine), and M4 (10 Ϫ8 mol/l pfluoro-hexahydro-sila-difenidol) receptors (Fig. 3, B and C) .
AT1 Receptor and M3 ACh Receptor Expression in CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ Mice
To further test whether the differential response to ANG II and ACh in mesenteric arteries of CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice resulted from differential receptor expression levels or different second messenger mechanisms, expression of AT1Rs and M3 ACh receptors in mesenteric arteries was analyzed (Fig. 4, A and B) . 2D Western blotting was used to detect AT1Rs, which are slightly but significantly expressed in mouse mesenteric arteries. The data show that expression of AT1R is significantly increased in mesenteric arteries of CXCR3Ϫ/Ϫ mice (1.84 Ϯ 0.13-fold upregulated, n ϭ 4, P Ͻ 0.05, t-test) compared with CXCR3ϩ/ϩ mice (Fig. 4A) . The expression of the M3 ACh receptor is considerably reduced in CXCR3Ϫ/Ϫ mice compared with CXCR3ϩ/ϩ mice ( Fig. 4B, right; 0.18 Ϯ 0.09-fold downregulated, n ϭ 3, P Ͻ 0.05, t-test). To confirm these data in another organ relevant for BP control, whole kidney protein extracts from CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ mice were tested. Our data show that in CXCR3Ϫ/Ϫ mice AT1R expression in whole kidney protein extracts was significantly increased compared with CXCR3ϩ/ϩ mice (1.24 Ϯ 0.04, n ϭ 3, P Ͻ 0.05, t-test; Fig. 4C ). 
Analysis of the Mouse AT1R Promoter Region
Recent data demonstrated that upregulation of AT1R expression in a human trophoblast cell line is regulated by the transcription factor SP-1, although additional transcription factors may also be involved (8) . Using the net-based search tool Alibaba 2.1, we identified putative SP-1 and EGR-1 overlapping binding sites in the murine AT1R promoter region (nucleotide Ϫ230/Ϫ51). It is known that SP-1 and the transcription factor EGR-1 share closely related DNA-binding sites and 1 and 2) . Mouse brain extract was loaded as a positive control (lane 3) and the specificity of the M3 AchR antibody was confirmed using a blocking peptide (lane 4). Quantifying signal intensities indicated that M3 AchR expression was significantly downregulated in CXCR3Ϫ/Ϫ mice (decreased 82 Ϯ 9% than CXCR3ϩ/ϩ mice, right plot, n ϭ 3, P Ͻ 0.05). C: expression of AT1R in whole kidney protein extracts from CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. Equal amounts of protein were analyzed by 2-dimensional Western blotting. Quantification of the signal intensities of spots representing AT1R (calibrated by actin signal intensity) revealed that AT1R expression in the kidney was significantly upregulated in CXCR3Ϫ/Ϫ mice (P Ͻ 0.05).
compete in numerous cell lines for the same promoter binding region influencing expression of numerous genes (5, 7, 8, 39, 42, 48) . To further test whether both transcription factors interact with putative binding sites in the AT1R promoter region, we used a double-strand mouse AT1R oligonucleotide corresponding to the nucleotide sequence Ϫ230/Ϫ51 in the murine AT1R promoter. Initial experiments found that the DBD of the SP-1 protein specifically bound to the biotinlabeled AT1R promoter region with high affinity (0.5 pmol; Fig. 5A, lane 4) . Binding of murine SP-1 DBD protein could be prevented by the addition of unlabeled mouse AT1R oligonucleotide (AT1R comp) corresponding to the nucleotide sequence Ϫ230/Ϫ51 in the murine AT1R promoter (Fig. 5A,  lane 5) . Notably, similar experiments using the same or even higher amounts (up to 5 pmol) of GST-tagged EGR-1 DBD protein revealed no binding to the murine AT1R promoter (Fig.  5B, lanes 2-6) . Initially, we used truncated protein versions comprising the zinc-finger DBDs of EGR-1 and SP-1, respectively. To confirm that the lack of GST-EGR-1 DBD interaction with the AT1R oligonucleotide is not based on improper folding during bacterial expression, the EMSAs were repeated using SP-1 and EGR-1 full-length proteins. Again, the SP-1 full-length protein specifically bound to the AT1R promoter region with high affinity (Fig. 5C ), whereas the GST-EGR-1 full-length protein (Fig. 5D ) and recombinant EGR-1 protein produced in insect cells (data not shown) failed to interact with the AT1R promoter region. To determine whether the GST-EGR-1 full-length protein is active and generally able to bind DNA fragments, competing experiments were performed using biotin-labeled EGR-1 consensus oligonucleotides and either a specific commercially available EGR-1 competitor (EGR-1 comp) or AT1R comp as the specific unlabeled competitor. The same amount of GST-EGR-1 full-length protein that failed to interact with AT1R (Fig. 5D, lane 2) was able to interact with the EGR-1 consensus oligonucleotides (Fig. 5E, lane 1) . As expected, the addition of a specific EGR-1 competitor (lanes 2 and 3) prevented binding, and notably the addition of AT1R comp. reduced binding of full-length EGR-1 protein to the EGR-1 consensus oligonucleotides (Fig. 5E, lanes 4 and 5) . To summarize, the data indicated that SP-1 protein bound with much greater affinity to the murine AT1R promoter region Ϫ230/Ϫ51 than did EGR-1 protein, which exhibited only little direct interaction with the promoter region.
To test whether EGR-1 influences SP-1 binding to the murine AT1R promoter region (230/Ϫ51), EMSA experiments were performed using constant quantities of SP-1 full-length and increasing quantities of EGR-1 full-length protein. As expected, SP-1 bound to the biotin-labeled AT1R promoter region as previously demonstrated (Fig. 6A, lane 6) . The addition of increasing amounts of EGR-1 full-length protein to the reaction mixture completely abolished binding of the SP-1 protein to the AT1R promoter region (Fig. 6A, lanes 7 and 8) . Notably, the same EGR-1 amounts used in the previous experiment and even higher amounts of EGR-1 protein without SP-1 protein in the reaction mixture did not affect the migration of biotin-labeled AT1R (Ϫ230/Ϫ51; see Fig. 6A , left, lanes [2] [3] [4] , indicating that recruitment of EGR-1 to the AT1R promotor requires SP-1. Interestingly, the addition of EGR-1 protein to the SP-1 protein/AT1R mixture caused a second shift of high molecular weight (Fig. 6A, lanes 7 and 8) , suggesting further protein-protein interaction between SP-1 and EGR-1 protein.
Previous studies demonstrated that not only DNA/protein interaction but also direct protein-protein interaction between SP-1 and EGR-1 influences the regulation of gene expression (44, 54) . To test whether expression levels of SP-1 and EGR-1 in CXCR3Ϫ/Ϫ mice might play a role in the regulation of AT1R expression, whole kidney protein extracts of CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ mice were tested for SP-1 and EGR-1 expression levels. Our data show that the expression level for EGR-1 remained unchanged between CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. In contrast, the expression level of SP-1 was slightly upregulated in CXCR3Ϫ/Ϫ mice (Fig. 6B) .
DISCUSSION
This study examined the impact of CXCR3 on cardiovascular function and its possible role in regulating BP. So far, chemokine receptors have been regarded mainly as effectors of immunological mechanisms such as inflammation, autoimmune disease, allograft rejection, lupus nephritis (47), and immune-mediated kidney disease (29) , but other works also revealed that CXCR3 is involved in ischemic nephropathy, renal endothelial microvascular injury, and renal fibrosis (12, 32, 35, 38, 41, 49) . Previous studies demonstrated that chemokine receptors can be expressed on various nonhematopoietic cells, including Purkinje cells (1, 11, 37, 50) , proximal tubular cells (3), podocytes, endothelial cells (10, 31) , and vascular smooth muscle cells (14) . Both endothelial and vascular smooth muscle cells are important in the pathogenesis of hypertension (43) . Moreover, dysfunction of vascular smooth muscle cells and endothelial cells has been implicated in the development of salt-dependent hypertension (17, 33) .
By using a CXCR3 knockout mouse model, we demonstrated that MAP was significantly higher in CXCR3Ϫ/Ϫ than in CXCR3ϩ/ϩ mice and additionally that hypertension in CXCR3Ϫ/Ϫ mice was salt sensitive, because an acute and chronic sodium load increased BP in CXCR3Ϫ/Ϫ mice. To further characterize the mechanisms of hypertension in CXCR3Ϫ/Ϫ mice, this study examined the vascular reactivity of CXCR3Ϫ/Ϫ mice.
Interestingly, the absence of CXCR3 led to increased AT1R expression in mesenteric arteries and whole kidney protein extracts, a finding that has been demonstrated in hypertensive transgenic animals for other receptors, such as the dopamine D4 and D5 receptor (4, 52, 53) . Furthermore, this study showed that vasoconstriction in response to ANG II was considerably increased in CXCR3Ϫ/Ϫ mice, and speculated that this increase results from increased AT1R expression in CXCR3Ϫ/Ϫ mice. The renin-angiotensin system fulfills a basic function in regulating arterial BP, and AT1R participate directly in the pathogenesis of cardiovascular and renal diseases (21) . The data presented here indicate that vasoconstriction in response to ANG II is increased in CXCR3Ϫ/Ϫ, contributing to hypertension in these animals. Additionally, the data support the hypothesis that vasodilatation in CXCR3Ϫ/Ϫ mice is also affected. The response to ACh via the muscarinic M3 receptor, a potent stimulator of vasodilatatory nitric oxide release (9, Fig. 6 . Recombinant EGR-1 protein reduces the binding of SP-1 full-length protein to the AT1R receptor promoter region. A, right: EMSAs were performed incubating the biotin-labeled AT1R promoter region with constant amounts of SP-1 full-length protein (1.5 BFU) and increasing amounts of EGR-1 full-length protein (5.6 and 11.6 pmol). Adding EGR-1 full-length protein to the reaction mixture prevented binding of the SP-1 full-length protein to the AT1 receptor promoter region (lanes 7 and 8) . Addition of EGR-1 protein created a second shift of high molecular weight (arrow), indicating EGR-1 and SP-1 protein interaction and binding of both proteins as a complex to the AT1 receptor promoter region. Left: in contrast, the same amount of EGR-1 full-length protein (5.6 -12 pmol) without SP-1 in the reaction mixture could not interact with the AT1R promoter region. B: expression level of transcription factors EGR-1 (left, arrow) and SP-1 (right, arrow) in whole kidney protein lysates from CXCR3ϩ/ϩ and CXCR3Ϫ/Ϫ mice. Bottom: loading control (Sypro Ruby staining). 20) , was reduced in vascular resistance vessels of CXCR3Ϫ/Ϫ mice, and additionally muscarinic M3 receptor expression in mesenteric arteries of CXCR3Ϫ/Ϫ mice was reduced in Western blot analyses. To summarize, the data indicate that both increased vasoconstriction and decreased vasodilatation contribute to hypertension in CXCR3Ϫ/Ϫ mice.
To further characterize the molecular mechanisms involved in BP regulation in CXCR3Ϫ/Ϫ mice, this study focused on the regulation of AT1R expression, which is relevant for cardiovascular disease (21) . Recent data demonstrated that upregulation of AT1R expression in a human trophoblast cell line is regulated by the transcription factor SP-1 (8) . This fits exactly to our observation that SP-1 protein expression was slightly increased in CXCR3Ϫ/Ϫ mice (Fig. 6B) . In addition, we found that SP-1 interacts with high affinity with the murine AT1R receptor region (Ϫ230/Ϫ51) providing an explanation that AT1R expression is increased in CXCR3Ϫ/Ϫ mice via an enhanced SP-1 expression.
However, regulation of AT1R expression seems to be much more complex. By using the net-based search tool Alibaba 2.1 (www.gene-regulation.com), we identified a putative SP-1/ EGR-1 overlapping binding site in the murine AT1R promoter region (Ϫ230/Ϫ51). EGR-1 and SP-1 have been shown to interact directly on the protein level, thus influencing direct DNA-protein interplay and the regulation of gene expression (44, 54) . In this study, we demonstrated that the SP-1 and EGR-1 protein interaction regulates the SP-1 binding to the murine AT1R binding site, because the addition of increasing concentrations of recombinant EGR-1 full-length protein prevented SP-1 from binding to the AT1R promoter region. Furthermore, the addition of EGR-1 protein to the reaction mix containing SP-1 protein and AT1R oligonucleotides caused a supershift, indicating that the two proteins interact and bind together to the AT1R promoter region. Regarding the study findings, it is interesting that interaction between the two proteins and the function of their interplay in gene expression have recently been described as a new regulatory mechanism (44, 48) . Srivastava et al. (44) described the EGR-1/SP-1 complex as a regulator of M-CSF gene expression and suggested that a decrease in EGR-1/SP-1 complex formation increased the binding of unbound SP-1 protein to the M-CSF promoter and thus stimulates protein expression. Recent studies suggest that not only the total protein expression of DNA-binding proteins but also the protein-protein interaction and the phosphorylation level of EGR-1 decide whether target proteins are expressed (44, 54) . Therefore, we speculate that an imbalanced EGR-1/SP-1 complex formation in CXCR3Ϫ/Ϫ mice results in an increased AT1R expression that leads to hypertension.
Analysis of polymorphisms in the sequences of GNAI2 gene promoter region from hypertensive humans showed that SP-1 might be associated with human essential hypertension (30) . Future experiments are necessary to further clarify the role of the transcription factors SP-1 and EGR-1 in BP control of CXCR3Ϫ/Ϫ mice and to further analyze the role of the M3 muscarinic ACh receptor in the pathophysiology of hypertension.
Recently, CXCR3 has been described as promoting renal fibrosis, a condition frequently associated with the development of hypertension (32) . However, recent data showed that CXCR3Ϫ/Ϫ and CXCR3ϩ/ϩ mice demonstrate identical serum creatinine and urea levels and comparable urinary albumin levels, indicating that renal disease is not a cause of hypertension in these animals (34) .
This study demonstrated that hypertension in CXCR3-deficient mice was salt sensitive; a finding that needs to be further clarified in future studies.
To summarize, this study demonstrates that blockade of CXCR3Ϫ/Ϫ mice causes hypertension, by upregulating AT1R, and thus leading to increased vasoconstriction, which in turn results in hypertension. Consequently, CXCR3 presents a new candidate gene for BP regulation and vascular reactivity in humans and offers a focus for hypertension therapy.
